Seres Therapeutics, Inc.

Seres Therapeutics announced it will host a webcast to discuss top-line results from an investigator-sponsored trial (IST) evaluating SER-155. The trial focuses on patients with immune checkpoint inhibitor-related enterocolitis (irEC), a serious side effect of cancer therapy. The webcast is scheduled for July 8, 2026, at 8:30 am ET, and will detail SER-155's potential as an immunosuppressive-free treatment to prevent interruption of cancer therapy. The IST involved 15 participants with moderate to severe irEC, with a primary endpoint of immunosuppressive-free clinical response by Day 15.

Seres Therapeutics announced two transactions to strengthen its balance sheet and extend its cash runway. The company will receive $25 million from Nestlé Health Science in two installments by October 2026, buying out potential future VOWST™ net sales-based milestones. Additionally, Seres restructured its lease agreement for its Cambridge, MA facility, reducing its leased space by approximately 45,832 square feet and decreasing long-term lease obligations by about $33.9 million. These actions are projected to extend the company's operating cash runway well into the first quarter of 2027.

Seres Therapeutics announced two transactions to strengthen its balance sheet and extend its operating cash runway well into Q1 2027. Nestlé Health Science will pay Seres $25 million in two installments in 2026 to buy out potential future VOWST net sales-based milestones. Additionally, Seres restructured a lease agreement for one of its facilities, significantly reducing leased space, annual cash costs, and long-term lease obligations. The company also anticipates clinical data from an investigator-sponsored SER-155 study later this month.

Seres Therapeutics, Inc. announced that Hans-Juergen Woerle, M.D., Ph.D. resigned from his position as a member of the board of directors, effective May 31, 2026. Dr. Woerle also resigned from the committees on which he served. The company stated that his departure was not due to any disagreement with Seres Therapeutics' operations, policies, or practices.

Seres Therapeutics, Inc. announced that its management will attend and present a company overview at the H.C. Wainwright 4th Annual BioConnect Investor Conference. The presentation is scheduled for May 19, 2026, at 3:30 p.m. ET, with a live webcast accessible via the company's website. Seres Therapeutics is a clinical-stage biotechnology company focused on inflammatory and immune diseases, known for developing VOWST and advancing pipeline candidates like SER-155 and SER-603.

Seres Therapeutics reported a net loss of $(19.9) million for the first quarter of 2026, a significant decline from a net income of $32.7 million in the prior year, largely due to the absence of the VOWST Business sale gain. The company's cash and cash equivalents fell to $29.8 million, leading management to conclude that substantial doubt exists regarding its ability to continue as a going concern. In response, Seres implemented cost reduction measures, including a 30% workforce reduction, and has paused further investment in its SER-155 Phase 2 study while actively seeking additional funding.

Seres Therapeutics reported a net loss of $19.9 million for the first quarter of 2026, a significant shift from the net income of $32.7 million in the same period last year. The company's cash and cash equivalents stood at $29.8 million as of March 31, 2026, with an anticipated cash runway extending through the third quarter of 2026. Operationally, Seres is awaiting clinical data from an investigator-sponsored SER-155 study and is advancing its inflammatory and immunology portfolio, including SER-603, while actively seeking partnerships and financing to support its pipeline.

Seres Therapeutics, Inc. filed its definitive proxy statement (DEF 14A) for its 2026 Annual Meeting of Stockholders, scheduled for June 9, 2026, at 8:00 a.m. Eastern Time. The meeting will be held virtually, and stockholders of record as of April 13, 2026, are eligible to vote. Key proposals include the election of three Class II Directors, ratification of the independent auditor, an advisory vote on executive compensation, and approval of an amendment to the 2025 Incentive Award Plan to increase available shares.